Reportedly, the collaboration spans a range of research projects.
Thomas Jensen, founder and CEO of Intomics, said: “We are extremely pleased to be working with LEO Pharma on their discovery projects. Using our unique expertise and biological data analysis technologies, we can facilitate fast, efficient research projects with improved results for LEO Pharma.
“Today, research projects generate large amounts of biological data, and sophisticated analyses of these are required to optimise the success rate of research projects. To facilitate this, both highly specialised know how and advanced tools are required.
“The synergy between LEO Pharma’s research in dermatology and critical care, and Intomics’ expertise in advanced biological analyses, will help face this challenge and lead to better, safer drugs – and ultimately benefit patients in these important areas.”